Navigation Links
TaiGen's Intravenous Taigexyn(R) Successfully Achieved Primary Endpoint in Phase 3 Clinical Trial for Community Acquired Pneumonia

TAIPEI, Taiwan, Dec. 3, 2015 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") made a public announcement today that the intravenous formulation of Taigexyn® has achieved the primary endpoint (clinical success rate at Visit 4 in the evaluable-mITT population) in the Phase 3 clinical trial of community acquired pneumonia (TG-873870-C-6). This trial was a randomized, double-blinded study comparing intravenous formulations of Taigexyn® 500mg vs. levofloxacin 500 mg and has recruited 525 patients from Taiwan and mainland China. The clinical success rates for Taigexyn® 500 mg and levofloxacin 500 mg were 92.8% and 87.0%, respectively, in evaluable-mITT subjects. Taigexyn® 500 mg was shown to be non-inferior to levofloxacin 500 mg in that the lower limit of the 95% CI of the treatment difference was greater than -10% (p<0.05). Based on these results, TaiGen will prepare for the filing of New Drug Application (NDA) with China's FDA in 2016.

About Taigexyn®

Taigexyn® (nemonoxacin) is designated as a Class 1.1 new drug under China's FDA.  It is a novel non-fluorinated quinolone with both oral and intravenous formulations. TaiGen have completed multiple clinical trials (Phase 1-3) for community acquired pneumonia in Taiwan and mainland China and have filed for NDA of the oral formulation in both markets in March and April 2013 respectively. The Taiwan FDA granted new drug license for the oral formulation of Taigexyn® to TaiGen in January 2015.

About TaiGen Biotechnology

TaiGen Biotechnology is a leading research-based and product-driven biotechnology company in Taiwan with a wholly-owned subsidiary in Beijing, China. In addition to Taigexyn®, TaiGen has two other in-house discovered NCEs in clinical development under IND with US FDA: TG-0054, a chemokine receptor antagonist for stem cell transplantation and chemosensitization and TG-2349, a HCV protease inhibitor for treatment of chronic hepatitis C infection, both in Phase 2.


Certain statements in this press release are forward-looking. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others.  These forward-looking statements are based on TaiGen's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain regulatory authority clearances or approvals and noncompliance with regulatory regulations.  As with any drugs under development, there are significant risks in the development, regulatory approval and commercialization of new products.  There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. TaiGen does not undertake an obligation to update or revise any forward-looking statement.

TaiGen Contact:
Peter W. Tsao, PhD, Vice President of Corporate Development
Tel: +886-2-8177-7072

SOURCE TaiGen Biotechnology
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. PMR Report: Global Peripheral Intravenous (I.V) Catheters Market to Account for US$ 5,224.7 Mn by 2021, Owing to Increase in the Number of Diseases
2. FDA Accepts Amgens New Drug Application For Novel Intravenous Calcimimetic Etelcalcetide
3. Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency
4. Amgen Submits New Drug Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416)
5. The World Market for Catheters (Urological, Intravenous, Cardiovascular Intervention, Angiography, Dialysis, PTCA, PICC, Oximetry and Surgical Catheters) to 2019
6. Independent Study Finds Intravenous Vernakalant Facilitates Electrical Cardioversion in Patients with Cardioversion Resistant Atrial Fibrillation
7. Global Intravenous Immunoglobulin (IVIG) Market is Expected to Reach $11.6 Billion, by 2021 - Allied Market Research
8. AcelRx Announces Publication of Manuscript Analyzing Cost of Intravenous Patient-Controlled Analgesia with Opioids
9. AcelRx Announces Publication of Sufentanil Sublingual Tablet System vs. Intravenous Patient-Controlled Analgesia with Morphine for Postoperative Pain Study Results
10. Global and Chinese Intravenous Catheter Industry Report 2014
11. Intravenous Access Devices Market is Expected to Reach USD 46.5 Billion Globally in 2019: Transparency Market Research
Post Your Comments:
(Date:3/30/2021)... ... March 29, 2021 , ... The University of Texas Health Science Center ... San Antonio Multispecialty and Research Hospital, a destination center for research and treatment of ... In a nod to the COVID-19 pandemic, the ceremony was held virtually. , William ...
(Date:3/30/2021)... ... March 29, 2021 , ... Iora Health ... primary care, has partnered with Devoted Health , one of the fastest-growing ... across Maricopa County and provides seniors with the highest-quality care and experience possible, ...
(Date:3/30/2021)... CITY (PRWEB) , ... March 29, 2021 , ... ... has joined the Vaccine Credential Initiative (VCI), a group bringing together leading health ... record of vaccination status, based on open, interoperable standards. By joining the VCI ...
Breaking Medicine Technology:
(Date:3/30/2021)... , ... March 29, 2021 , ... ... the 21st Century , A Virtual Workshop Presented by WCG FDAnews and Cerulean ... 4:30 pm EDT, , Are one’s SOPs written for the ...
(Date:3/30/2021)... ... March 29, 2021 , ... According to data released ... reproductive age (13-44) in need of publicly funded contraception live in counties impacted by ... Colorado’s 64 counties have lost some of their Title X resources. , The ...
(Date:3/30/2021)... ... March 29, 2021 , ... Health Literacy Innovations (HLI), a ... confusion due to low health literacy today announces a new partnership with the ... work with ACAP’s member Safety Net Health Plans, those that provide comprehensive health ...
(Date:3/30/2021)... ... ... Dr. Colin Campbell is proud to announce the 1 year anniversary in their new state ... internal medicine and is a primary care specialist who has been practicing for 23 years. ... keep South Jersey healthy one patient at a time. , “Over the past year, Dr. ...
(Date:3/30/2021)... ... March 30, 2021 , ... The COVID-19 ... and survivors; their families; and their caregivers. Crossroads4Hope is addressing the needs of ... emotional support system, MyGo2Support, which meets needs of people impacted by cancer, no ...
Breaking Medicine News(10 mins):